OxSonics Therapeutics

0 followers


OxSonics® Therapeutics’ proprietary platform technology, SonoTran®, is being developed to provide a step-change in the therapeutic index of anti-cancer agents without the development costs or delays associated with drug reformulation. SonoTran is designed to increase the dose and distribution of ant... Read more

Industries

Headquarters

Stage

Employees

Links

Org chart

Jérome Marzinski, MBA
Chief Executive Officer

Jérome Marzinski, MBA

Collapse
Andrew Rogers
Director RAQA
Cliff Rowe
Development Director
David Preston
Finance Director
Glyn Edwards
Non Executive Director
Ruth Barrett
Senior Manager, Programmes And Contracts